| NASDAQ (usa) |
 |
6715.56 | -12.11 | -0.18% |
| FTSE 100 (london) |
|
7487.96 | -5.12 | -0.07% |
| DAX (german) |
 |
13465.51 | 235.94 | 1.78% |
| NIKKEI 225 (japan) |
|
22420.08 | 408.47 | 1.86% |
| Hang - Seng (hong kong) |
|
28594.06 | 348.52 | 1.23% |
| NIFTY - 50 (india) | ||||
| Straits Times (singapore) |
|
3391.61 | 17.53 | 0.52% |
| KOSPI (korea) |
|
2556.47 | 33.04 | 1.31% |
| All Ordinaries (australia) |
|
6005.30 | 28.90 | 0.48% |
| BOVESPA (brazil) |
|
74092.76 | -215.73 | -0.29% |
Repligen Corporation (NASDAQ: RGEN)
RGEN Technical Analysis
5
| As on 9th Jun 2023 RGEN SHARE Price closed @ 162.19 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 190.76 & Strong Sell for SHORT-TERM with Stoploss of 208.50 we also expect STOCK to react on Following IMPORTANT LEVELS. |
RGENSHARE Price
| Open | 163.64 | Change | Price | % |
| High | 164.58 | 1 Day | -2.04 | -1.24 |
| Low | 159.35 | 1 Week | -8.83 | -5.16 |
| Close | 162.19 | 1 Month | 12.64 | 8.45 |
| Volume | 378875 | 1 Year | -103.23 | -38.89 |
| 52 Week High 269.70 | 52 Week Low 140.68 | ||||
NASDAQ USA Most Active Stocks
| TSLA | 244.40 | 4.06% |
| TTOO | 0.07 | -12.50% |
| SOFI | 8.18 | 0.74% |
| FFIE | 0.33 | 6.45% |
| PONO | 1.72 | 2.38% |
| AMD | 124.92 | 3.20% |
| IDEX | 0.06 | 0.00% |
| NKLA | 0.70 | 14.75% |
| AMZN | 123.43 | -0.66% |
| AAPL | 180.96 | 0.22% |
NASDAQ USA Top Gainers Stocks
NASDAQ USA Top Losers Stocks
| RGEN Daily Charts |
RGEN Intraday Charts |
Whats New @ Bazaartrend |
RGEN Free Analysis |
|
|
RGEN Important Levels Intraday
| RESISTANCE | 172.27 |
| RESISTANCE | 169.04 |
| RESISTANCE | 167.04 |
| RESISTANCE | 165.04 |
| SUPPORT | 159.34 |
| SUPPORT | 157.34 |
| SUPPORT | 155.34 |
| SUPPORT | 152.11 |
RGEN Forecast April 2024
| 4th UP Forecast | 272.57 |
| 3rd UP Forecast | 237.17 |
| 2nd UP Forecast | 215.29 |
| 1st UP Forecast | 193.41 |
| 1st DOWN Forecast | 130.97 |
| 2nd DOWN Forecast | 109.09 |
| 3rd DOWN Forecast | 87.21 |
| 4th DOWN Forecast | 51.81 |
RGEN Weekly Forecast
| 4th UP Forecast | 208.26 |
| 3rd UP Forecast | 193.49 |
| 2nd UP Forecast | 184.35 |
| 1st UP Forecast | 175.22 |
| 1st DOWN Forecast | 149.16 |
| 2nd DOWN Forecast | 140.03 |
| 3rd DOWN Forecast | 130.89 |
| 4th DOWN Forecast | 116.12 |
RGEN Forecast2024
| 4th UP Forecast | 425.96 |
| 3rd UP Forecast | 341.37 |
| 2nd UP Forecast | 289.08 |
| 1st UP Forecast | 236.79 |
| 1st DOWN Forecast | 87.59 |
| 2nd DOWN Forecast | 35.3 |
| 3rd DOWN Forecast | -16.99 |
| 4th DOWN Forecast | -101.58 |
Repligen Corporation ( NASDAQ USA Symbol : RGEN )
Sector : Healthcare And Other Stocks in Same Sector
Sector : Healthcare And Other Stocks in Same Sector
RGEN Business Profile
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company offers filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and SpectraFlo dynamic dialysis systems; and ProConnex single-use hollow fiber. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE and FlowVPE brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands; and Sartorius Stedim Biotech to create novel perfusion-enabled bioreactors. Repligen Corporation was incorporated in 1981 and is headquartered in Waltham, Massachusetts. Address: Building 1, Waltham, MA, United States, 02453
© 2005-2023 BazaarTrend.com All rights reserved.
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service
Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service